MedPath

Effect of systematic lifestyle advice & use of cholesterol reducing drugs on cardiovascular disease outcomes among men with newly diagnosed prostate cancer on androgen deprivation therapy.

Phase 3
Conditions
Health Condition 1: C61- Malignant neoplasm of prostate
Registration Number
CTRI/2023/07/054807
Lead Sponsor
Dr Jehonathan Pinthus Dr Leong Darryl
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients with diagnosed prostate cancer who are either

a) Newly diagnosed (i.e. the diagnosis was made within 1 year of the enrolment visit), or

b) Treated with ADT for the first time within 6 months prior to the enrolment visit,

or

c) To be treated with ADT for the first time within 1 month after the enrolment visit

Exclusion Criteria

Patients will be excluded if they fulfill any of the following:

a) Are unwilling to provide consent, or

b) Are <45 years of age, or

c) Prostate cancer was found incidentally following cystectomy for bladder cancer

Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:

a) See a cardiologist every year, or

b) Both take a statin and have systolic blood pressure =130mm of Hg

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure, or arterial revascularization.Timepoint: 3-5 years
Secondary Outcome Measures
NameTimeMethod
1.Occurrence of composite all-cause mortality, myocardial infarction, stroke, or heart failure <br/ ><br>2.Composite of cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, or unstable, new or worsening angina, <br/ ><br>3.Cardiovascular death <br/ ><br>4.Myocardial infarction <br/ ><br>5.Stroke <br/ ><br>6.Heart failure <br/ ><br>7.Venous thromboembolism <br/ ><br>Timepoint: 3-5 years
© Copyright 2025. All Rights Reserved by MedPath